ALDO

ALDO - General Information

A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)

Pharmacology of ALDO

ALDO is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. ALDO has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. ALDO has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.

ALDO for patients

ALDO Interactions

An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion,
extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL. A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.

As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS
depressants such as anesthetics, opiates, and alcohol.

In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline. In 5 other schizophrenic patients treated with oral haloperidol and rifampin,
discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations. Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.

ALDO Contraindications

Since the pharmacologic and clinical actions of HALDOL Decanoate 50 and HALDOL Decanoate 100 are attributed to HALDOL (haloperidol) as the active medication, Contraindications, Warnings, and additional information are those of HALDOL, modified only to reflect the prolonged action. HALDOL is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have Parkinsonís disease.

Additional information about ALDO

ALDO Indication: For the treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy also used in Tourette's syndrome and Severe hyperactivity.Mechanism Of Action: The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known. Its effect on the central nervous system is thought to be associated with the competitive blockade of postsynaptic dopamine D2 receptors in the mesolimbic dopaminergic system and an increased turnover rate of brain dopamine.Drug Interactions: Anisotropine Methylbromide The anticholinergic increases the risk of psychosis and tardive dyskinesia
Atropine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Belladona The anticholinergic increases the risk of psychosis and tardive dyskinesia
Benztropine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Biperiden The anticholinergic increases the risk of psychosis and tardive dyskinesia
Clidinium The anticholinergic increases the risk of psychosis and tardive dyskinesia
Dicyclomine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Ethopropazine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Glycopyrrolate The anticholinergic increases the risk of psychosis and tardive dyskinesia
Homatropine Methylbromide The anticholinergic increases the risk of psychosis and tardive dyskinesia
Hyoscyamine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Isopropamide The anticholinergic increases the risk of psychosis and tardive dyskinesia
Methantheline The anticholinergic increases the risk of psychosis and tardive dyskinesia
Mepenzolate The anticholinergic increases the risk of psychosis and tardive dyskinesia
Orphenadrine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Oxyphencyclimine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Procyclidine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Propantheline The anticholinergic increases the risk of psychosis and tardive dyskinesia
Trihexyphenidyl The anticholinergic increases the risk of psychosis and tardive dyskinesia
Tridihexethyl The anticholinergic increases the risk of psychosis and tardive dyskinesia
Scopolamine The anticholinergic increases the risk of psychosis and tardive dyskinesia
Thioridazine Increased risk of cardiotoxicity and arrhythmias
Mesoridazine Increased risk of cardiotoxicity and arrhythmias
Rifampin The rifamycin decreases the effect of haloperidol
Rifabutin The rifamycin decreases the effect of haloperidol
Propranolol Increased effect of both drugs
Methyldopa Methyldopa increases haloperidol effect or risk of psychosis
Lithium Possible extrapyramidal effects and neurotoxicity with this combination
Ketoconazole The imidazole increases the effect and toxicity of haloperidol
Itraconazole The imidazole increases the effect and toxicity of haloperidol
Fluconazole The imidazole increases the effect and toxicity of haloperidol
Clozapine Clozapine increases the effect and toxicity of haloperidol
Guanethidine The agent decreases the effect of guanethidine
Atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
Carbamazepine Carbamazepine decreases the effect of haloperidolFood Interactions: Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.Generic Name: HaloperidolSynonyms: Not AvailableDrug Category: Antidyskinetics; Antipsychotics; Antiemetics; Butyrophenones; Dopamine AntagonistsDrug Type: Small Molecule; ApprovedOther Brand Names containing Haloperidol:ALDO; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Apo-Haloperidol; Bioperidolo; Brotopon; Dozic; Dozix; Einalon S; Eukystol; Galoperidol; Haldol; Haldol Decanoate; Haldol La; Haldol Solutab; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidol Decanoate; Haloperidol Intensol; Haloperidol Lactate; Halopidol; Halopoidol; Halosten; Keselan; Lealgin Compositum; Linton; Mixidol; Novo-Peridol; Pekuces; Peluces; Peridol; Pernox; Pms Haloperidol; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium;Absorption: Oral-60%Toxicity (Overdose): LD50=165 mg/kg (rats, oral)Protein Binding: 92%Biotransformation: HepaticHalf Life: 3 weeksDosage Forms of ALDO: Liquid Oral
Tablet Oral
Solution Oral
Liquid IntramuscularChemical IUPAC Name: 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-oneChemical Formula: C21H23ClFNO2Haloperidol on Wikipedia: http://en.wikipedia.org/wiki/HaloperidolOrganisms Affected: Humans and other mammals